Sign up
Pharma Capital

ValiRX confirms online publication of peer-reviewed article

VAL401 is a new formulation of the antipsychotic drug risperidone
The article can now be read online

Drug developer ValiRx Plc (LON:VAL) has confirmed its peer-reviewed article analysing the used of lead drug, VAL401, has now been published online in the European Journal of Drug Metabolism and Pharmacokinetics.

The academic work focuses on data from a phase II study, completed last year in Tbilisi, Georgia.

READ: New long-term NHS plan bodes well for ValiRx

ValiRx said in December the report was intended to be the first in a series of results-based publications on the treatment.

VAL401 is a new formulation of the antipsychotic drug risperidone, which researchers have transformed into a potential oncology treatment.

The article can be viewed by clicking on this link here.

View full VAL profile View Profile
View All

Related Articles

Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.